新型冠状病毒黏膜疫苗研究进展  

Research progress on mucosal vaccines for SARS-CoV-2

作　　者：张佳璐 张旋旋 毛群颖[1] 梁争论[1] 贺倩 ZHANG Jialu;ZHANG Xuanxuan;MAO Qunying;LIANG Zhenglun;HE Qian(National Institutes for Food and Drug Control,Beijing 100260,China)

机构地区：[1]中国食品药品检定研究院,北京100260

出　　处：《中国病毒病杂志》2023年第6期419-427,共9页Chinese Journal of Viral Diseases

摘　　要：新型冠状病毒(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2,简称新冠病毒)引起的新冠病毒感染(coronavirus disease 2019,COVID-19)在全球范围的大流行,对人类健康造成严重危害,开发有效预防新冠病毒感染的疫苗尤为重要。早期获批紧急使用或附条件上市的新冠病毒疫苗以诱导系统免疫应答为主,无法刺激足够的黏膜应答。黏膜疫苗可同时诱导呼吸道黏膜免疫应答及全身系统免疫应答,形成抵御新冠病毒入侵的黏膜免疫屏障,是预防新冠病毒感染的理想疫苗。本文综述新冠病毒黏膜疫苗研究进展,总结呼吸道黏膜疫苗研发面临的挑战及未来发展方向,为呼吸道黏膜疫苗研发提供思路。The global pandemic of coronavirus disease 2019(COVID-19)caused by the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)poses a serious threat to human health,highlighting the importance of the development of effective vaccines to prevent SARS-CoV-2 infections.The SARS-CoV-2 vaccines that were approved for emergency use or conditionally marketed in the early days primarily induce systemic im-mune responses,but did not stimulate sufficient mucosal immune responses.Mucosal vaccines,which can induce both systemic and respiratory mucosal immune responses,and can form a mucosal immune barrier against invasion of SARS-CoV-2,are ideal for preventing SARS-CoV-2 infections.This paper summarizes the research progress on mucosal vaccines for SARS-CoV-2 and discuss the challenges and future directions,so as to shed some light on research and development of respiratory mucosal vaccines.

关 键 词：新型冠状病毒 疫苗 黏膜免疫 黏膜疫苗递送系统 免疫原性评价 

分 类 号：R183.3[医药卫生—流行病学]